Abstract: Diabetic retinopathy is a leading complication of diabetes. Death of capillary cells with resulting capillary degeneration is a central feature of this disease. Chronic low-grade inflammation has been linked to the development of retinal capillary degeneration in diabetes. CD40 is an upstream inducer of a broad range of inflammatory responses in the diabetic retina and is required for death of retinal capillary cells. Recent studies uncovered CD40 as a novel inducer of purinergic signaling and identified the CD40-ATP-P2X 7 pathway as having a key role in the induction of inflammation in the diabetic retina and programmed cell death of retinal endothelial cells.
Introduction
Diabetes is one of the most common chronic diseases in the world. The prevalence of diabetes worldwide in 2014 increased to 8.5% in adults over 18 years of age leading to the estimation that there are 422 million patients with diabetes in the world [1] . Microangiopathy is a major cause of morbidity and mortality in diabetics and the retina is one of the main tissues affected by diabetic microvascular disease. The overall prevalence of diabetic retinopathy (DR) is 35% among individuals with diabetes [2] . Moreover, DR is the leading cause of vision loss among individuals from 20 to 74 years of age in the United States [3] .
Retinal vascular pathology is a key cause of clinically significant loss of vision in diabetics. Early vascular lesions of DR include the death of retinal endothelial cells and pericytes [4] . This leads to the transformation of capillaries into tubes of basement membrane devoid of cells (capillary degeneration). Degenerate retinal capillaries lack blood flow [5] and thus contribute to the development of retinal ischemia and subsequent neovascularization in advanced diabetic retinopathy. Neovascularization and macular edema are leading causes of vision loss in DR.
Various mechanisms appear to link chronic hyperglycemia to the development of microangiopathy. These include oxidative stress, increased polyol pathway flux, increased hexosamine pathway flux, activation of protein kinase C and increased formation of advanced glycation-end products [6] . Chronic low grade inflammation also plays an important role in the pathogenesis of DR [7] . ICAM-1 is upregulated in retinal endothelial cells in diabetic retinas from humans and rodents, and ICAM-1 promotes an increase in the number of leukocytes adherent to vessel walls (leukostasis) in diabetic rats [8, 9] . Blockade of ICAM-1 diminishes capillary degeneration in diabetic mice [10] . Retinal levels of inducible nitric oxide synthase (NOS2) are increased of patients with DR and in diabetic rodents [11, 12] . Moreover, diabetic NOS2 −/− mice are protected from retinal leukostasis and capillary degeneration [13, 14] . The vitreous fluid in patients with proliferative DR [15] and retinas of diabetic rodents [16] exhibit increased expression of the chemokine (C-C motif) ligand 2 (CCL2, also known as monocyte chemoattractant protein 1 or MCP-1). CCL2 recruits leukocytes including monocytes and dendritic cells to sites of inflammation. The correlation between CCL2 protein levels in the vitreous with the clinical stage of diabetic proliferative retinopathy [17] suggests a pathogenic role for this chemokine.
CD40 is Required for Development of Experimental DR
Increasing evidence indicates that CD40 is a key upstream regulator of various inflammatory responses in the diabetic retina and a central mediator of the development of experimental DR [18] [19] [20] [21] . CD40 is a TNF receptor superfamily member expressed on various hematopoietic and non-hematopoietic cells [22] [23] [24] . CD154 (CD40 ligand) is expressed on activated T cells and platelets, and can also be present in plasma as a soluble protein [22, 23] . In addition to retinal microglia/macrophages, non-hematopoietic cells including retinal endothelial cells (REC), Müller cells and retinal ganglion neurons have constitutive low-level expression of CD40 [25] .
The CD40-CD154 pathway is activated in diabetes: CD40 expression is increased in Müller cells, REC and microglia/macrophages in diabetic mice [20] , and blood levels of CD154 are increased in diabetic mice and patients with microangiopathy [21, [26] [27] [28] . Moreover, serum CD154 from diabetics induces pro-inflammatory responses in endothelial cells and monocytes [28] . Studies in diabetic CD40 −/− mice revealed that CD40 is central to ICAM-1 upregulation in REC, leukostasis, upregulation of TNF-α, IL-1β and NOS2 retinal mRNA levels, retinal protein nitration and increased CCL2 mRNA in the retina [19] [20] [21] . In addition, diabetic CD40 −/− mice do not develop capillary degeneration indicating that CD40 is critical for early experimental DR [20, 21] . In vitro studies also support the importance of CD40 as a key mediator of inflammatory responses in retinal cells. CD40 ligation causes upregulation of ICAM-1, CCL2, NOS2 and PGE 2 in Müller cells and/or REC [19] . CD40 stimulation in macrophages/microglia increases TNF-α and IL-1β secretion and upregulates NOS2 [29] [30] [31] . Myeloid cells are central mediators of inflammation. However, studies using bone marrow transplants in a mouse model of ischemia/reperfusion-induced retinopathy (a CD40-driven disease) revealed the importance of CD40 expressed on non-hematopoietic cells for the development of ischemic retinopathy. The induction of retinal inflammation with the resulting increase in ganglion neuron loss in this model requires expression of CD40 in non-hematopoietic cells but not in hematopoietic cells [32] . In addition, we recently uncovered a novel mechanism by which CD40 on non-hematopoietic cells (Müller cells) induces by-stander macrophages/microglia to express pro-inflammatory cytokines and promote development of experiment diabetic retinopathy [21, 33] .
Müller cells are the main macroglia in the retina. These cells become dysfunctional in diabetes and contribute to the development of experimental DR [34] . Transgenic mice on a CD40 −/− background that exhibit rescue of CD40 restricted to Müller cells (Trg-CD40 mice) were generated to study the role of CD40 expressed in Müller in the pathogenesis of DR [21] . After becoming diabetic, these mice exhibit upregulation of TNF-α, IL-1β, ICAM-1, NOS2 and CCL2 in the retina and develop capillary degeneration (early experimental DR) [21] . Diabetic transgenic mice without rescue of CD40 (Trg-Ctr mice) do not upregulate these pro-inflammatory molecules and do not develop capillary degeneration [21] . Interestingly, in vitro studies revealed that while Müller cells secrete CCL2 in response to CD40 ligation, these cells do not produce TNF-α and IL-1β in response to this stimulation [19, 21] . These findings raised the possibility that CD40 stimulation in Müller cells recruits other retinal cells to upregulate TNF-α and IL-1β. Indeed, co-culture experiments of Müller cells and monocyte/macrophages showed that CD40 ligation causes release of extracellular ATP by in Müller cells that in turn triggers TNF-α and IL-1β secretion by monocytes/macrophages that is mediated by the purinergic receptor P2X 7 expressed on these myeloid cells [21] . Several lines of evidence support the in vivo relevance of the newly discovered CD40-ATP-P2X 7 pathway in experimental DR. Retinal microglia/macrophages are the cells that upregulate TNF-α protein levels both in diabetic Trg-CD40 mice and in diabetic wild-type (WT) animals [21, 35] . Diabetic Trg-CD40 mice treated with the P2X 7 inhibitor BBG and diabetic P2X 7 −/− mice do not upregulate TNF-α and IL-1β, as well as NOS2 and ICAM-1, molecules induced by TNF-α/IL-1β [21] . Further support of the relevance of CD40-ATP-P2X 7 pathway in experimental DR comes from the demonstration that both diabetic Trg-CD40 mice and WT mice upregulate P2X 7 protein levels in retinal microglia/macrophages [21] . This finding is significant because P2X 7 upregulation is a key feature of P2X 7 -driven diseases and increased P2X 7 expression in microglia is sufficient to stimulate pro-inflammatory cytokine expression [36] . Taken together, these results suggest that the CD40-ATP-P2X 7 pathway is a central mediator of upregulation of TNF-α, IL-1β, NOS2 and ICAM-1 in the diabetic retina ( Figure 1 ).
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The studies discussed herein uncovered CD40 as a key mediator of DR. It remains to be determined how CD40 is upregulated in diabetes and how CD154 gains access to the retina. The discovery of the CD40-ATP-P2X 7 pathway provided the first definitive demonstration that an inflammatory disorder can develop when CD40 is expressed exclusively in a non-hematopoietic cell. This finding is likely to have therapeutic implications. CD40 is a recognized target for the treatment of various diseases with an inflammatory component. Signaling pathways downstream of CD40 have different relative roles in the induction of inflammatory responses in hematopoietic vs. non-hematopoietic cells [19, 30] . CD40-TNF Receptor Associated Factor 6 (TRAF6) is the signaling pathway by which CD40 induces inflammatory responses in myeloid cells [30, 51] , but is also central to the activation of various cell-mediated immune responses required for control of intracellular pathogens [30, 31, 51, 52] . Thus, attempts to inhibit CD40 signaling active in myeloid cells have the risk of causing susceptibility to opportunistic infections. While CD40-TRAF6 signaling also promotes inflammatory responses in non-hematopoietic cells, blockade of CD40-TRAF2 signaling is sufficient to markedly impair these responses in non-hematopoietic cells including Müller cells [19, 30, 53] . Moreover, the CD40-TRAF2 pathway does not play a significant role in the induction cell-mediated immune responses [30, 31, 51, 52] . The demonstration that CD40 signaling in Müller cells activates inflammatory responses not only in Müller cells but also in bystander microglia/macrophages suggests that inhibitors of CD40-TRAF2 signaling may effectively inhibit inflammation at the level of both non-hematopoietic and myeloid cells in DR.
